Final dosimetry results of IDEC-Y2B8 phase I II 90yttrium radioimmunothenapy trial in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Wiseman, GA
White, CA
Witzig, TA
Stabin, MG
Spies, S
Silverman, DH
Raubitschek, A
Gordon, L
Emmanouilides, C
Janakiraman, N
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 1999年 / 40卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
260
引用
收藏
页码：64P / 64P
页数：1
相关论文
共 50 条
  • [1] IDEC-Y2B8 (90)yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a Phase I/II trial.
    Witzig, T
    Wiseman, C
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanoulides, C
    Royston, I
    Parker, E
    Chinn, P
    GrilloLopez, A
    BLOOD, 1997, 90 (10) : 2606 - 2606
  • [2] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma
    Gregory A. Wiseman
    Christine A. White
    Michael Stabin
    William L. Dunn
    William Erwin
    Magnus Dahlbom
    Andrew Raubitschek
    Kastytis Karvelis
    Timothy Schultheiss
    Thomas E. Witzig
    Richard Belanger
    Stewart Spies
    Daniel H. S. Silverman
    Judy R. Berlfein
    Eric Ding
    Antonio J. Grillo-López
    European Journal of Nuclear Medicine, 2000, 27 : 766 - 777
  • [3] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    Wiseman, GA
    White, CA
    Stabin, M
    Dunn, WL
    Erwin, W
    Dahlbom, M
    Raubitschek, A
    Karvelis, K
    Schultheiss, T
    Witzig, TE
    Belanger, R
    Spies, S
    Silverman, DHS
    Berlfein, JR
    Ding, E
    Grillo-Lópezs, AJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (07) : 766 - 777
  • [4] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90yttrium anti-CD20 monoclonal antibody.
    Wiseman, G
    Witzig, T
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanouilides, C
    Gutheil, J
    Parker, E
    Chinn, P
    Grillo-Lopez, A
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 59 - 59
  • [5] Zevalin™ (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL):: Interim results.
    Gordon, LI
    White, CA
    Witzig, TE
    Flinn, I
    Czuczman, M
    Wiseman, GA
    Spies, S
    Olejnik, T
    Zhang, C
    Grillo-Lopez, AJ
    Lurie, RH
    BLOOD, 1999, 94 (10) : 91A - 91A
  • [6] Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
    Witzig, TE
    White, CA
    Wiseman, GA
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Parker, E
    Grillo-López, AJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3793 - 3803
  • [7] Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
    GrilloLopez, AJ
    Chinn, P
    Morena, R
    Varns, C
    Parker, E
    Solinger, AM
    BLOOD, 1995, 86 (10) : 207 - 207
  • [8] IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
    Maloney, DG
    GrilloLopez, AJ
    Bodkin, DJ
    White, CA
    Liles, TM
    Royston, I
    Varns, C
    Rosenberg, J
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) : 3266 - 3274
  • [9] Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Bitran, J. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
  • [10] Phase I/II trial of clofarabine in refractory and/or relapsed non-hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Gozun, P.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345